此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

伊布替尼治疗复发或难治性滤泡性淋巴瘤患者

2026年11月10日 更新者:National Cancer Institute (NCI)

单药 Ibrutinib (PCI-32765) 在复发或难治性滤泡性淋巴瘤中的 2 期试验

This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. Evaluate the overall response rate of ibrutinib in patients with relapsed or refractory follicular lymphoma.

SECONDARY OBJECTIVES:

I. Assess the safety and tolerability of ibrutinib in patients with follicular lymphoma.

II. Evaluate overall survival, time to response, duration of response, progression-free survival, time to treatment failure, and time to subsequent treatment.

TERTIARY OBJECTIVES:

I. Describe the relationship between interim positron emission tomography (PET)/computed tomography (CT) scan results, CT response, and response duration.

II. Biomarker studies including exploring associations between ibrutinib response and somatic mutations identified in follicular lymphoma, whole transcriptome shotgun sequencing (ribonucleic acid-sequencing [RNA-seq]), exploration of inhibition of Bruton's tyrosine kinase (BTK) and other kinases, expression of cytokines, chemokines, and other proteins with an aim to develop predictors of response and resistance.

III. Assess changes in various cancer-derived molecules in the blood over the course of treatment with ibrutinib.

IV. As part of ongoing research for Phase II Consortium (P2C) studies, we are banking paraffin-embedded tissue blocks/slides and blood products for future studies.

OUTLINE:

Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.

After completion of study treatment, patients are followed up every 3 months until progressive disease, and then every 6 months for 5 years.

研究类型

介入性

注册 (实际的)

41

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Hamilton、Ontario、加拿大、L8V 5C2
        • Juravinski Cancer Centre at Hamilton Health Sciences
      • Kingston、Ontario、加拿大、K7L 2V7
        • Kingston Health Sciences Centre
      • Toronto、Ontario、加拿大、M5G 2M9
        • University Health Network-Princess Margaret Hospital
      • Singapore、新加坡、119074
        • National University Hospital Singapore
      • Singapore、新加坡、168583
        • National Cancer Centre Singapore
    • Arizona
      • Scottsdale、Arizona、美国、85259
        • Mayo Clinic in Arizona
    • Florida
      • Jacksonville、Florida、美国、32224-9980
        • Mayo Clinic in Florida
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic in Rochester
      • Saint Louis Park、Minnesota、美国、55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Louis Park、Minnesota、美国、55416
        • Metro Minnesota Community Oncology Research Consortium
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19111
        • Fox Chase Cancer Center
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed diagnosis of follicular lymphoma, grade 1, 2, or 3a

    • Note: Fresh (frozen) tumor biopsy must be available or attempted; a frozen tumor biopsy equivalent to a minimum of four at least 16 gauge needle cores is an important component of this study; patients without adequate frozen material should have a biopsy performed to obtain material; if biopsy is performed and does not yield adequate material, the patient is still eligible for the study; if a biopsy cannot be done safely, the patient may still be eligible for the study if permission is granted in writing (email) by the study chair (Dr. Nancy Bartlett) or her designees; Dr. Bartlett may be consulted to discuss situations involving invasive biopsy procedures that may pose an increased risk to the patient
  • Measurable disease as defined by a lymph node or tumor mass that is >= 1.5 cm in at least one dimension by CT or the CT portion of the PET/CT

  • Relapsed or refractory follicular lymphoma which has progressed during or following 1 or more prior chemotherapy regimens for lymphoma

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

  • Absolute neutrophil count >= 750/mm^3 (0.75 x 10^9/L)

  • Hemoglobin >= 8.0 g/dL

  • Platelets >= 30,000/mm^3 (30 x 10^9/L)

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless Gilbert's syndrome or disease infiltration of the liver is present

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x institutional ULN

  • Creatinine =< 2.0 x institutional ULN

  • Creatinine clearance (estimated [est.] glomerular filtration rate [GFR] Cockcroft-Gault) >= 30 mL/min

  • Negative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential only

  • Ability to understand and the willingness to sign a written informed consent document

  • Willingness to provide biologic samples for correlative research purposes

Exclusion Criteria:

  • Any of the following:

    • Chemotherapy/systemic therapy =< 4 weeks prior to registration
    • Radiotherapy =< 4 weeks prior to registration
    • Nitrosoureas or mitomycin C =< 6 weeks prior to registration
    • Those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
    • Major surgery =< 10 days prior to registration or minor surgery =< 7 days prior to registration
    • Prior therapy with ibrutinib or another Bruton's tyrosine kinase inhibitor
    • Receiving any other investigational agents
  • Active central nervous system (CNS) involvement

  • Receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 family 3 subfamily A member 4/5 (CYP3A4/5)

  • Any of the following:

    • Pregnant women

    • Nursing women

    • Men or women of childbearing potential who are unwilling to employ adequate contraception

      • Note: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ibrutinib administration
      • Note: Breastfeeding should be discontinued if the mother is treated with ibrutinib
  • Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

    • Note: HIV-positive patients who are not on anti-viral medications that are strong CYP3A4/5 inhibitors and who do not have cluster of differentiation (CD)4 counts less than the lower limit of normal by institutional criteria are eligible; no patients with CD4 counts below institutional normals are eligible
  • Known active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)

  • Known histological transformation from follicular lymphoma to diffuse large B-cell lymphoma

    • Note: A prior history of adequately treated transformed lymphoma does not exclude a patient if the current active disease is biopsy-proven follicular lymphoma
  • History of stroke or intracranial hemorrhage =< 6 months prior to the first dose of study drug

  • Requires anticoagulation with warfarin or similar vitamin K antagonist

    • Note: Warfarin or similar vitamin K antagonist must have been discontinued at least 28 days prior to study entry
  • Patient has the inability to swallow tablets

  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection,
    • Uncontrolled diabetes mellitus
    • Cardiac disease
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • "Currently active" second malignancy, other than non-melanoma skin cancers

    • Note: Patients are not considered to have a "currently active" malignancy if they have completed anti-cancer therapy, and are considered by their physician to be at less than 30% risk of relapse
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib

  • Concurrent treatment with therapeutic doses (> 20 mg prednisone or equivalent) of systemic steroids within 14 days of start of protocol therapy

  • Prior history of allogeneic stem cell transplant

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (ibrutinib)

Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.

Correlative studies

Given PO

其他名称:
  • PCI-32765
  • 因布鲁维察
  • BTK 抑制剂 PCI-32765
  • CRA-032765
  • PCI32765
  • 加拿大税务局 032765
  • CRA032765
  • PCI 32765

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Response Rate
大体时间:Up to 5 years

Overall response rate defined as a partial response (PR) or complete response (CR) as the objective status at any time during treatment, evaluated using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.

A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen.

Up to 5 years

次要结果测量

结果测量
措施说明
大体时间
Duration of Response
大体时间:Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented, assessed up to 5 years

Duration of response is defined as the time from first evidence of a response to the first documented time of progressive disease (PD). Response and Progression were assessed using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. > > A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen.Estimated using the method of Kaplan-Meier.>

> Progressive Disease (PD) is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented, assessed up to 5 years
Overall Survival
大体时间:Assessed up to 5 years

Overall Survival is defined as the time from registration to death due to any cause. Estimated using the method of Kaplan-Meier.

Assessed up to 5 years
Progression-free Survival
大体时间:Time from registration to progression or death due to any cause, assessed up to 5 years

Progression-Free Survival is defined as the time from registration to documented progression or death due to any cause, whichever occurs first. Estimated using the method of Kaplan-Meier.

Time from registration to progression or death due to any cause, assessed up to 5 years
Time to Response
大体时间:Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR, assessed up to 5 years

Time to response is defined for all evaluable patients who have achieved a confirmed response as the time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR.The median and 95% confidence interval will be calculated using the methods of Kaplan-Meier.

Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR, assessed up to 5 years
Time to Subsequent Treatment
大体时间:Time from registration to the date of initiation of subsequent treatment for lymphoma, assessed up to 5 years

Time to subsequent treatment is defined as the time from registration to the date of initiation of subsequent treatment for lymphoma. The distribution of time to subsequent treatment will be estimated using the method of Kaplan-Meier.

Time from registration to the date of initiation of subsequent treatment for lymphoma, assessed up to 5 years
Time to Treatment Failure
大体时间:Time from registration to the date of treatment discontinuation due to any reason, assessed up to 5 years

Time to treatment failure is defined as the time from registration to the date of treatment discontinuation due to any reason. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.

Time from registration to the date of treatment discontinuation due to any reason, assessed up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nancy L Bartlett、Mayo Clinic

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年4月2日

初级完成 (实际的)

2016年6月3日

研究完成 (估计的)

2027年3月19日

研究注册日期

首次提交

2013年5月6日

首先提交符合 QC 标准的

2013年5月6日

首次发布 (估计的)

2013年5月8日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NCI-2013-00887
  • P30CA015083 (美国 NIH 拨款/合同)
  • U10CA180821 (美国 NIH 拨款/合同)
  • N01CM00099 (美国 NIH 拨款/合同)
  • N01CM00032 (美国 NIH 拨款/合同)
  • NCI-2013-00887 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • MC1282
  • 9271 (其他标识符:CTEP)
  • 9271 (其他标识符:Mayo Clinic in Rochester)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅